SBIR/STTR Research Award

A Diarylheptanoid Scaffold to Treat Taopathies

Award identifier a73d4c9c5458673251037bc819643260ee96b424c877744ba69acd5f21d793acAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,999

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CFD Research Corporation
Proposal award date
Not reported
Contract end date
Not reported
UEI
V3KCP1HNFM33
Solicitation number
PA12-088
Topic code
NIGMS

Research abstract

DESCRIPTION: Pulmonary drug delivery is increasingly used for both treatment of lung diseases (such as asthma and chronic obstructive pulmonary disease) and in delivering drugs to the systemic circulation. To reach the desired effectiveness and safety oforally/nasally inhaled drugs, appropriate deposition of drugs on targeted region is essential. Due to complex pharmaceutical and physiological factors underlying bioavailability of inhaled drug products, computational modeling tools are urgently required to provide mechanistic insights of involved delivery processes and to estimate efficacy of pulmonary drug delivery in an accurate and efficient manner. Therefore, in this project, we propose to develop a novel multi-scale computational tool to simulate deposition, dissolution, absorption, transport, clearance, and actions of inhaled drug products within an integral framework of computational fluid dynamics (CFD) and PBPK-PD models. In Phase I, we will (1.) develop the hybrid CFD model of particle depositionin the entire human airways, (2.) extend the CFD models accounting for various physiological and pathological settings, and (3.) integrate CFD deposition models with pharmacokinetic models to estimate various pharmaceutical and physiological factors on pulmonary drug delivery. The associated computational investigations will greatly facilitate drug development by identifying key biopharmaceutical factors affecting efficacy and safety of inhaled drugs. In Phase II, we will further improve the computational tool model developed in Phase I by focusing on integration with physiology and compound databases, model calibration/validation, development of the software GUI, and demonstration of more pharmaceutical applications. The proposed computational tool will provide a mechanism-based virtual platform to investigate interactions between drug delivery systems and physiological/pathological systems, to provide mechanistic insights into key aspects affecting efficacy and safety of inhaled drug products, and to guideoptimal designs of pulmonary drug delivery systems. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The novel software tool proposed in this project will provide an efficient and accurate computational platform to virtually test, design, anddevelop inhaled drug products by investigating interactions between pulmonary delivery systems and the human physiological systems at multiple scales. Applications of the proposed computational tool will reveal key aspects affecting fate of administered drugs and consequent therapeutic or toxic effects. Hence, the developed computational tool will meet urgent demands from pharmaceutical and biomedical industries by accelerating drug discovery and development processes, by facilitating translational applications from bench to bedside, by increasing success rates of new pulmonary drug products, and by ultimately helping reduce health care burdens on society.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

947 SBIR/STTR records share this UEI (1987–2026). Reported award amounts total $350,893,199. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Health and Human Services, National Science Foundation, Department of Commerce, Department of Energy

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.